HOUSTON, March 3, 2020 /PRNewswire/ -- CNS
Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"),
a biopharmaceutical company specializing in the development of
novel treatments for primary and metastatic cancers of the brain
and central nervous system, announces as of February 2020, a patient from the Phase 1
clinical trial for the treatment of glioblastoma multiforme
("GBM"), conducted by Reata Pharmaceuticals, Inc., remains cancer
free. GBM is an aggressive type of brain cancer and, currently,
there are no effective therapies approved to treat this
disease.
In the Phase 1 trial, 44% of patients experienced a
statistically significant improvement in progression-free survival.
This 44% disease control rate was based on 11 patients (out of 25
evaluable patients) with stable disease, plus responders. One
patient experienced a durable complete response, which is defined
by the National Cancer Institute as the disappearance of all signs
of cancer in response to treatment. This initial trial was
conducted in 2006 and as of February
2020, the patient has remained cancer free for over 13
years.
"We are delighted to provide this update on Berubicin's
potential capabilities given the unmet need for this aggressive
disease," commented John M. Climaco,
Chief Executive Officer of CNS Pharmaceuticals. "We are
looking forward to initiating our Phase 2 clinical trial in the
second half of this year with our partner, WPD Pharmaceuticals,
Inc. In addition, we expect WPD Pharmaceuticals, Inc. to commence a
first-ever Phase 1 trial in children later this year. As previously
announced, the pediatric trial will be conducted at Children's
Memorial Health Institute, the largest pediatric hospital in
Poland." WPD Pharmaceuticals, Inc.
was founded by Dr. Waldemar Priebe,
the founder of the Company.
About Berubicin
Berubicin is an anthracycline, a class
of anticancer agents that are among the most powerful chemotherapy
drugs and effective against more types of cancer than any other
class of chemotherapeutic agents. Anthracyclines are designed to
utilize natural processes to induce deoxyribonucleic acid (DNA)
damage in targeted cancer cells by interfering with the action of
topoisomerase II, a critical enzyme enabling cell proliferation.
Berubicin treatment of brain cancer patients appeared to
demonstrate positive responses that include one durable complete
response in a Phase 1 human clinical trial conducted by Reata
Pharmaceuticals, Inc.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is developing novel treatments for primary and
metastatic cancers of the brain and central nervous system. Its
lead drug candidate, Berubicin, is proposed for the treatment of
GBM, an aggressive and incurable form of brain cancer. CNS holds a
worldwide exclusive license to the Berubicin chemical compound and
has acquired all data and know-how from Reata Pharmaceuticals, Inc.
related to a completed Phase 1 trial with Berubicin in GBM which
Reata conducted in 2006. In this trial, 44% of patients
experienced a statistically significant improvement in
progression-free survival. This 44% disease control rate was based
on 11 patients (out of 25 evaluable patients) with stable disease,
plus responders. One patient experienced a durable complete
response and remains cancer-free as of February 20, 2020. In the second half of 2020,
CNS expects to commence a Phase 2 clinical trial of Berubicin for
the treatment of GBM in the U.S., while a sub-licensee partner
undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial
in pediatric GBM patients in Poland. Its second drug
candidate, WP1244, is a novel DNA binding agent that has been shown
in preclinical studies to be 500-times more potent than the
chemotherapeutic agent daunorubicin in inhibiting tumor cell
proliferation. For more information, please visit
www.cnspharma.com.
Forward-Looking Statements
Some of the statements in
this press release are forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934 and the Private Securities
Litigation Reform Act of 1995, which involve risks and
uncertainties. Forward-looking statements in this press release
include, without limitation, the ability of the Company to
initiates its Phase 2 clinical trial in the second half of this
year, and the ability of WPD Pharmaceuticals to commence a Phase 1
trial in children later this year. These statements relate to
future events, future expectations, plans and prospects. Although
CNS believes the expectations reflected in such forward-looking
statements are reasonable as of the date made, expectations may
prove to have been materially different from the results expressed
or implied by such forward-looking statements. CNS has attempted to
identify forward-looking statements by terminology including
''believes,'' ''estimates,'' ''anticipates,'' ''expects,''
''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,''
''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or
other words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. These statements are
only predictions and involve known and unknown risks, uncertainties
and other factors, including those discussed in the Company's SEC
filings, including under the heading "Risk Factors" in the Form S-1
filed on October 7, 2019. Any
forward-looking statements contained in this press release speak
only as of its date. CNS undertakes no obligation to update any
forward-looking statements contained in this press release to
reflect events or circumstances occurring after its date or to
reflect the occurrence of unanticipated events.
View original
content:http://www.prnewswire.com/news-releases/cns-pharmaceuticals-announces-brain-cancer-patient-from-berubicin-phase-1-trial-remains-cancer-free-301015066.html
SOURCE CNS Pharmaceuticals, Inc.